Drugs / Gliclazide MR
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT02925559 Comparator | Oct 2016 → Feb 2018 | type 2 diabetes mellitus | Centro de Diabetes Curitiba Ltda | Completed | No outcome recorded |
| — | NCT01420692 Comparator | Jun 2010 → Apr 2012 | type 2 diabetes mellitus | Ankara University | Completed | No outcome recorded |
| — | NCT00506194 Comparator | Oct 2005 → Aug 2007 | type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gliclazide MR | “The subjects will start with Gliclazide-MR 30mg before breakfast” NCT00506194 ↗ |
| Modality | Small molecule | “addition of sulfonylurea (gliclazide MR)” NCT01420692 ↗ |
| Route | Oral | “Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.” NCT01420692 ↗ |